Paul Kusserow - Amedisys CEO and President and Director
| AMED Stock | USD 92.77 0.12 0.13% |
CEO
Mr. Paul B. Kusserow is President, Chief Executive Officer, Director of Amedisys, Inc. Mr. Kusserow is our President and Chief Executive Officer and was a member of our Board of Directors since joining our Company in December 2014. Previously, he was Vice Chairman and President of Alignment Healthcare, Inc., an integrated clinical care and health plan company, from June 2014 until December 2014. From December 2013 until June 2014, Mr. Kusserow served as a consultant for Boston Consulting Group, where he advised Amedisys on corporate strategy. Before that, he served as Senior Vice President, Chief Strategy, Innovations and Corporationrationrate Development Officer of Humana, Inc., a healthcare services and benefits company, from February 2009 through December 2013. Prior to joining Humana, Inc., he was Managing Director and Chief Investment Officer of the Ziegler HealthVest Fund, a VC fund focused on early to midstage investments in healthcare services, healthcare technology and wellness a cofounder and Managing Director of San Ysidro Capital Partners, L.L.C., an investment advisory and management firm specializing in healthcare services and technology and Managing Partner of Roaring Mountain, L.L.C., a strategy consulting and investment management firm with large clients in healthcare services and technology. Mr. Kusserow began his healthcare career with Tenet Healthcare Corporationrationration, one of the nations largest investorowned healthcare service companies, where he spent seven years, the last four as Senior Vice President, Strategy and Tenet Ventures. He began his career as a management consultant at McKinsey Company. He has served on many corporate and advisory boards, and currently serves on the Boards of Directors of Oak Street Health, Picwell, Inc., and Matrix Medical Network. He previously served on the Board of Directors of Connecture, Inc., New Century Health, Inc., AxelaCare Health Solutions, Inc since 2014.
| Age | 63 |
| Tenure | 11 years |
| Phone | 225 292 2031 |
| Web | https://www.amedisys.com |
Amedisys Management Efficiency
The company has return on total asset (ROA) of 0.0624 % which means that it generated a profit of $0.0624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0332 %, meaning that it created $0.0332 on every $100 dollars invested by stockholders. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | CEO Age | ||
| Theodore CPA | Healthcare Services Group | 51 | |
| Dirk CPA | Addus HomeCare | 69 | |
| Stephen Flatt | National HealthCare | 69 | |
| Patrick Blair | InnovAge Holding Corp | 54 | |
| April Anthony | Encompass Health Corp | 53 | |
| Dirk Allison | Addus HomeCare | 68 | |
| John Rademacher | Option Care Health | 58 | |
| Christopher Christensen | The Ensign Group | 56 | |
| Mark Tarr | Encompass Health Corp | 63 | |
Management Performance
| Return On Equity | 0.0332 | ||||
| Return On Asset | 0.0624 |
Amedisys Leadership Team
Elected by the shareholders, the Amedisys' board of directors comprises two types of representatives: Amedisys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amedisys. The board's role is to monitor Amedisys' management team and ensure that shareholders' interests are well served. Amedisys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amedisys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael North, Senior Vice President - Operations | ||
| John Nugent, Chief Officer | ||
| Pete Hartley, CTO Systems | ||
| Kendra Kimmons, VP Relations | ||
| Jennifer Griffin, Chief Secretary | ||
| Janet Britt, VP Collections | ||
| Francis Mayer, Senior Development | ||
| Keith Blanchard, Acting Officer | ||
| Richard Ashworth, CEO President | ||
| Scott CPA, COO, VP | ||
| Allyson Guidroz, Chief Officer | ||
| Scott Ginn, Chief Accounting Officer | ||
| Denise Bohnert, Chief Officer | ||
| Paul Kusserow, CEO and President and Director | ||
| Caitlin Franklin, Acting Officer | ||
| Nick Muscato, Vice President of Strategic Finance | ||
| Adam Holton, Chief Officer |
Amedisys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amedisys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0332 | ||||
| Return On Asset | 0.0624 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 3.19 B | ||||
| Shares Outstanding | 32.81 M | ||||
| Shares Owned By Insiders | 2.09 % | ||||
| Shares Owned By Institutions | 91.60 % | ||||
| Number Of Shares Shorted | 2.74 M | ||||
| Price To Earning | 15.03 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.